Role of hsCRP as an indicator of prognosis in acute coronary syndrome

 

Ashok Thaned¹, Triveni Ayyanna^2*, Sunil K³

 

REFERENCES

1. Murray CJL, Lopez AD. Alternative projection of mortality and morbidity by cause 1990-2020; Global Burden of Disease Study. Lancet 1997; 349:1498-15
2. Gupta et al. CHD in India .Annals of Global Health, VOL. 82, NO. 2 , 2016 March-April 2016 : 307 -315
3. Marcello Rattazi, Massimo Puato, Elisabetta Faggin, Barbara Bertipaglia, Alberto Zambon, Paolo Pauletto, C-reactive protein and interleukin-6 in vascular disease;culprits or passive bystanders? Journal of Hypertension, 2003; 21(10): 1787-1803.
4. Narasinga Rao Siddanathi, N.Hemalatha, K.Indira Devi, B.V.Chandrakala, G.V.Hari Krishna. A Study on Role of Circulating HscrpAs A Biomarker of Clinical Significance in Acute Mi And Identification of Extent of Involvement, Risk Assessment And Post Mi Complications. IJAR ,May 2016;p95-99
5. Foussas SG, Zairis MN, Lyras AG, Patsourakos NG, Tsirimpis VG, Katsaros K et al, Early prognostic usefulness of C reactive protein added to thrombolysis in myocardial infarction risk score in acute coronary syndromes, Am. J. Car, Aug 2005; 96; p 533-537.
6. Suleiman M, Aronson D, Reisner SA, Kapeliovich MR, Markiewicz W, Levy Y et al, Admission C reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am Jr of Med; Dec 2003, 115; 9 p 695-701
7. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study), Am Heart J, June 1963, 65; p 749-757
8. PS Singh, G.Singh, SK Singh et al, Clinical profile and risk factors in acute coronary syndrome. Journal, Indian Academy of clinical Medicine 2013;vol.14 No.2:130-2
9. BibiKulsoom ,S.NazrulHasnain. Association of Serum C-Reactive Protein and LDL/HDL with Myocardial Infarction . JPMA 56:318:2006.
10.  Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999;19:1986–91.
11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95. 
12.  Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–44. 
13. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006;166:2073–80.
14. Deepak Y. Kamath, Denis Xavier, Alben Sigamani, and Prem PaisHigh sensitivity C-reactive protein (hsCRP) and cardiovascular disease: An Indian perspective Indian journal of medical research . 2015 Sep; 142(3): 261–268.
15. Francisco Antonio Helfenstein Fonseca and Maria Cristina de Oliveira Izar High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities Clinics (Sao Paulo). 2016 Apr; 71(4): 235–242.
16. Pearson T.A., Mensah G., Alexander R.W. AHA/CDC scientific statement – markers of inflammation and cardiovascular disease. Circulation. 2003;107:499–511.